Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine
Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon th...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-03-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2016.1241358 |
| _version_ | 1797674585403949056 |
|---|---|
| author | Eva Hong Aude Terrade Muhamed-Kheir Taha |
| author_facet | Eva Hong Aude Terrade Muhamed-Kheir Taha |
| author_sort | Eva Hong |
| collection | DOAJ |
| description | Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero® vaccine. We tested the immunogenicity and safety of this vaccine among adults laboratory staff using the recommended schedule of 2 doses at 5 weeks interval. The vaccine was well tolerated in spite of frequent local side effects and all participants reported at least one side effect after each dose. Immunogenicity was evaluated 6 weeks and one year after the second dose. All participants showed increase in their bactericidal titers against the components of the vaccine 6 weeks after the second dose, however titers declined significantly one year later. |
| first_indexed | 2024-03-11T22:02:10Z |
| format | Article |
| id | doaj.art-ef880a1b9e414f7db9739c45dc75e802 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:02:10Z |
| publishDate | 2017-03-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-ef880a1b9e414f7db9739c45dc75e8022023-09-25T11:00:54ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2017-03-0113364564810.1080/21645515.2016.12413581241358Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccineEva Hong0Aude Terrade1Muhamed-Kheir Taha2Invasive Bacterial Infections Unit and National Reference Centre for MeningococciInvasive Bacterial Infections Unit and National Reference Centre for MeningococciInvasive Bacterial Infections Unit and National Reference Centre for MeningococciNeisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero® vaccine. We tested the immunogenicity and safety of this vaccine among adults laboratory staff using the recommended schedule of 2 doses at 5 weeks interval. The vaccine was well tolerated in spite of frequent local side effects and all participants reported at least one side effect after each dose. Immunogenicity was evaluated 6 weeks and one year after the second dose. All participants showed increase in their bactericidal titers against the components of the vaccine 6 weeks after the second dose, however titers declined significantly one year later.http://dx.doi.org/10.1080/21645515.2016.1241358immunogenicitylaboratory workersneisseria meningitidisvaccinesafety |
| spellingShingle | Eva Hong Aude Terrade Muhamed-Kheir Taha Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine Human Vaccines & Immunotherapeutics immunogenicity laboratory workers neisseria meningitidis vaccine safety |
| title | Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine |
| title_full | Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine |
| title_fullStr | Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine |
| title_full_unstemmed | Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine |
| title_short | Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine |
| title_sort | immunogenicity and safety among laboratory workers vaccinated with bexsero r vaccine |
| topic | immunogenicity laboratory workers neisseria meningitidis vaccine safety |
| url | http://dx.doi.org/10.1080/21645515.2016.1241358 |
| work_keys_str_mv | AT evahong immunogenicityandsafetyamonglaboratoryworkersvaccinatedwithbexserovaccine AT audeterrade immunogenicityandsafetyamonglaboratoryworkersvaccinatedwithbexserovaccine AT muhamedkheirtaha immunogenicityandsafetyamonglaboratoryworkersvaccinatedwithbexserovaccine |